28 citations,
November 2003 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” The normal human prostate does not significantly affect blood DHT levels.
January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
1 citations,
June 2010 in “Mayo Clinic Proceedings” The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
August 2002 in “Analytical Sciences” The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.
Enemas can cause septicemia in elderly men with prostate infections.
12 citations,
February 2010 in “Asian Journal of Animal and Veterinary Advances” Young and adult hamsters both respond similarly to testosterone and finasteride treatments, but young hamsters aren't good for testing the inhibitory activity of a specific enzyme.
56 citations,
January 2015 in “Circulation” Finasteride helps reduce heart issues and improves heart function.
10 citations,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
14 citations,
August 2021 in “Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy” Metformin, a diabetes drug, may help prevent and treat various cancers, but more research is needed.
11 citations,
November 2009 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Bolandiol, a synthetic steroid, builds muscle and bone without greatly affecting sex glands, and works differently from other hormones.
June 2006 in “American Journal of Epidemiology” Long-term diabetes is linked to lower prostate cancer risk.
June 2006 in “American Journal of Epidemiology” Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.
17 citations,
January 2016 in “American Journal of Epidemiology” Men with male pattern baldness have a higher risk of dying from prostate cancer.
1 citations,
May 2013 in “Journal of the Egyptian Women's Dermatologic Society (Print)” PSA could be a marker for hyperandrogenism in women, but more research is needed.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
402 citations,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
148 citations,
April 2009 in “Molecular Pharmaceutics” Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
147 citations,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
72 citations,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
66 citations,
June 2006 in “Journal of The American Academy of Dermatology” Finasteride increases hair weight and count in men with hair loss, with best results after four years.
66 citations,
April 2002 in “Journal of The American Academy of Dermatology” Finasteride increases hair weight and count in men with hair loss.
57 citations,
January 1986 in “The Prostate” The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
49 citations,
August 2009 in “British Journal of Cancer” Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
18 citations,
March 2009 in “Medical Hypotheses” The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.
16 citations,
April 2007 in “Journal of Obstetrics and Gynaecology Research” Prostate-specific antigen may be a new marker for excess male hormones in women with polycystic ovary syndrome.
12 citations,
March 2013 in “Cancer Causes & Control” Early balding, especially frontal, increases prostate cancer risk; more research needed.
7 citations,
October 2017 in “Urologic Oncology: Seminars and Original Investigations” Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.
4 citations,
March 2018 in “Journal of labelled compounds & radiopharmaceuticals” A new compound was effective for imaging prostate cancer in rats.